BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 6321685)

  • 1. Treatment of small cell lung cancer with VP-16, vincristine, doxorubicin (Adriamycin), cyclophosphamide (EVAC), and high-dose chest radiotherapy.
    Goodman GE; Miller TP; Manning MM; Davis SL; McMahon LJ
    J Clin Oncol; 1983 Aug; 1(8):483-8. PubMed ID: 6321685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [VP-16, vincristine, adriamycin and cyclophosphamide (EVAC) in patients with small-cell lung cancer].
    Abad-Esteve A; Rosell R; Moreno I; Fernández-Marcial C; Roselló M; Ribas Mundó M
    Med Clin (Barc); 1988 Apr; 90(14):569-72. PubMed ID: 2840536
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of small cell lung cancer].
    Kawahara M; Tsuruta M; Furuse K; Arai R; Kodama N; Yamamoto M; Kubota K; Nakai R; Ogawara M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):457-62. PubMed ID: 2831819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of cyclophosphamide, doxorubicin, and vincristine (CAV) and etoposide plus cisplatin (EP) alternating chemotherapy combined with radiotherapy in small cell lung cancer.
    Park YJ; Koh EH; Kim J; Roh JK; Chang J; Ahn CM; Sohn HY; Kim SK; Lee WY; Kim K
    Yonsei Med J; 1989; 30(1):30-7. PubMed ID: 2545051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].
    Ohnoshi T; Hiraki S; Ueoka H; Kawahara S; Numata T; Nishii K; Yonei T; Yamashta H; Kiura K; Kozuka A
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1341-8. PubMed ID: 2543304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer.
    Evans WK; Osoba D; Feld R; Shepherd FA; Bazos MJ; DeBoer G
    J Clin Oncol; 1985 Jan; 3(1):65-71. PubMed ID: 2981293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    Einhorn LH; Crawford J; Birch R; Omura G; Johnson DH; Greco FA
    J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung.
    Beith JM; Clarke SJ; Woods RL; Bell DR; Levi JA
    Eur J Cancer; 1996 Mar; 32A(3):438-43. PubMed ID: 8814688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.
    Collins C; Higano CS; Livingston RB; Griffin BR; Keppen MD; Miller TP
    Cancer Chemother Pharmacol; 1989; 24(2):128-32. PubMed ID: 2543513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CAV-PVP chemotherapy and sequential thoracic irradiation (TI) for patients with limited (LD) small cell lung cancer (SCLC)].
    Ueoka H; Ohnoshi T; Hiraki S; Kamei H; Tabata M; Shibayama T; Miyatake K; Gemba K; Hiyama J; Kimura I
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():218-24. PubMed ID: 8007469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
    Kies MS; Mira JG; Crowley JJ; Chen TT; Pazdur R; Grozea PN; Rivkin SE; Coltman CA; Ward JH; Livingston RB
    J Clin Oncol; 1987 Apr; 5(4):592-600. PubMed ID: 3031226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternating chemotherapy with cyclophosphamide/adriamycin/vincristine (CAV) and cisplatin/etoposide (PVP) against small cell lung cancer. Eastern Shikoku Lung Cancer Chemotherapy Group.
    Bando H; Takishita Y; Ogura T; Sone S; Shimizu E; Nakayama T; Doi H; Kobayashi M
    Jpn J Clin Oncol; 1991 Dec; 21(6):435-9. PubMed ID: 1666660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A combination chemotherapy consisting of vincristine, etoposide and cyclophosphamide (VEC) for small cell carcinoma of the lung].
    Adachi K; Ogawa M; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Usui N; Nakata H; Tada A; Aiba K
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1617-22. PubMed ID: 6089668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.